<table>
<thead>
<tr>
<th>タイトル</th>
<th>Title</th>
<th>Induction Chemotherapy with Docetaxel, Cisplatin and 5-fluorouracil for Tongue Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>著者</td>
<td>Author(s)</td>
<td>Shibuya, Yasuyuki / Tanimoto, Hiroshi / Umeda, Masahiro / Yokoo, Satoshi / Komori, Takehide</td>
</tr>
<tr>
<td>掲載誌・巻号・ページ</td>
<td>Citation</td>
<td>The Kobe journal of the medical sciences,50(1/2):1-7</td>
</tr>
<tr>
<td>刊行日</td>
<td>Issue date</td>
<td>2004-03</td>
</tr>
<tr>
<td>資源タイプ</td>
<td>Resource Type</td>
<td>Departmental Bulletin Paper / 紀要論文</td>
</tr>
<tr>
<td>版区分</td>
<td>Resource Version</td>
<td>publisher</td>
</tr>
<tr>
<td>権利</td>
<td>Rights</td>
<td></td>
</tr>
<tr>
<td>DOI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>JaLCDOI</td>
<td>10.24546/00408173</td>
<td></td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://www.lib.kobe-u.ac.jp/handle_kernel/00408173">http://www.lib.kobe-u.ac.jp/handle_kernel/00408173</a></td>
<td></td>
</tr>
</tbody>
</table>

PDF issue: 2018-12-18
Induction Chemotherapy with Docetaxel, Cisplatin and 5-fluorouracil for Tongue Cancer

YASUYUKI SHIBUYA, HIROSHI TANIMOTO, MASAHIRO UMEDA, SATOSHI YOKOO, and TAKAHIDE KOMORI

Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine

Received 5 January 2004/ Accepted 25 March 2004

Key words: docetaxel; cisplatin; 5-FU; induction chemotherapy; tongue cancer

Induction chemotherapy consisting of one cycle of docetaxel, cisplatin and 5-fluorouracil (5-FU) was evaluated for its primary effects on squamous cell carcinoma of the tongue. The patients were five men and one woman, 50 to 67 (mean 57.8) years of age. Clinical staging of the tongue cancers showed two patients with stage III and four with stage IV disease. All patients underwent one cycle of intravenous chemotherapy with docetaxel (60 mg/m², on day 1), cisplatin (10 mg/m², from days 1 to 5) and 5-FU (500 mg/body, from days 1 to 5) before surgical operation. The overall response rate was 83.3% (five PRs and one NC), with two cases with grade II A in the Ohboshi & Shimosato classification and four with grade II B. The main side effect was severe neutropenia, which was effectively managed with granulocyte colony-stimulating factor (G-CSF).

In conclusion, induction chemotherapy with docetaxel, cisplatin and 5-FU for tongue cancer was tolerated well by all the patients and showed an excellent response rate in spite of only one cycle of administration.

Although patients with oral cancer in the early stages (I and II) are often cured by radiotherapy or surgery alone, patients in more advanced stages (III and IV) frequently require a multimodality approach to obtain satisfactory results. Cisplatin and continuous infusion of 5-fluorouracil (5-FU) have been established as the standard induction regimen for advanced cases [1,2]. For head and neck cancers, this regimen has produced response rates of 60-90% and complete response (CR) rates of 20-50% [1,3,4].

Docetaxel is an effective agent which when used alone, has produced response rates of 21-42% for patients with locally advanced, recurrent, and/or metastatic disease [5,6,7]. Docetaxel differs in its mechanism of action from cisplatin and 5-FU. Therefore, some investigators have examined combining these agents to achieve better response and cure rates. Thus, we also examined an induction chemotherapy regimen consisting of docetaxel, cisplatin and 5-FU in one cycle of administration for the treatment of advanced squamous cell carcinoma of the tongue, a major oral cancer.

PATIENTS AND METHODS

This study included six patients with untreated squamous cell carcinoma of the tongue who were treated between December 2001 and March 2003 (Table I). The patients comprised five men and one woman, 50 to 67 (mean 57.8) years of age. Two patients had
stage III and four had stage IV disease. The performance status (ECOG) of all patients was less than II. The study protocol was approved by our Institutional Review Board, and all patients went through an informed consent process.

All patients received one cycle of intravenous chemotherapy with docetaxel (60 mg/m², on day 1 for 1 hour), cisplatin (10 mg/m², from days 1 to 5, for two hours) and 5-FU (500 mg/body, from days 1 to 5, continuous infusion) as the induction treatment (Table II). Side effects were assessed in accordance with “Common Toxicity Criteria v. 2.0” [8]. One month after the start of chemotherapy, clinical responses were assessed by inspection, palpation and CT-scan or magnetic resonance imaging (MRI). The tumor regression rate was defined as the percentage reduction achieved in the cross-sectional area of a measurable tumor through use of the product of the 2 largest perpendicular diameters and the following formula:

\[
\text{Tumor regression rate (\%)} = \left( \frac{1-\text{tumor size after preoperative therapy}}{\text{pretreatment tumor size}} \right) \times 100.
\]

Disappearance of all known disease due to the chemotherapy was evaluated as a complete response (CR). A partial response (PR) was defined as a tumor regression rate of at least 50%, while no change (NC) was less than 50% or more than –25%.

This assessment was followed by radical surgery, and the histological effects were evaluated based on Ohboshi & Shimosato classification [9] using the surgical specimens.

**RESULTS**

The results are presented in Table I. The overall response rate with this regimen was 83.3%. CR was not observed, but PR was obtained in five cases. Only one patient was evaluated as NC, whose primary lesion was located at the rear of the dorsal tongue. This patient died 6 months after the radical surgery. The histological assessment of all cases showed destruction of tumor structures as a result of the chemotherapy. In four cases, there was severe destruction and a few viable tumor cells that were assessed as grade II B
according to the Ohboshi & Shimosato classification. On the other hand, the remaining two cases, including the one NC, were assessed as grade II A because destruction was incomplete and many viable tumor cells were observed. Severe side effects of more than grade III were leukopenia, neutropenia, thrombocytopenia, alopecia and diarrhea. Alopecia occurred in five cases a few weeks after the start of chemotherapy. The nadirs of leukopenia (three cases) and neutropenia (four cases) were observed between days 6 and 10 but were manageable with granulocyte colony-stimulating factor (G-CSF). Thrombocytopenia and diarrhea were observed in only one case each. As mild side effects of less than grade III, nausea (three cases), and vomiting, stomatitis and dizziness (one case each) were also found.

**Case 1**

Case 1 was a 67-year-old male with left tongue cancer (T3N0M0). After one cycle of the induction chemotherapy, a marked response was observed and the tumor regression rate was determined at 60% by palpation, resulting in an assessment of PR (Figs.1 and 2). The patient underwent left radical neck dissection and a hemiglossectomy reconstructed with a rectus abdominis myocutaneous flap. The histological effect was evaluated as II B (Fig.3).

![Fig.1. Left tongue cancer of case 1 before chemotherapy (T3N0M0).](image1.png)

![Fig.2. Left tongue cancer after one cycle of induction chemotherapy of case 1. Clinical response is assessed as PR.](image2.png)

![Fig.3. Histological findings of case 1 after chemotherapy. Tumor structures are destroyed severely and only a few viable tumor cells are observed. These findings are assessed as grade II B according to the Ohboshi & Shimosato classification.](image3.png)

**Case 2**

Case 2 was a 50-year-old male with left tongue cancer (T4N2cM0). After one cycle of the induction chemotherapy, marked response was observed but evaluation by palpation was difficult. MRI showed a tumor regression rate of 51% that was evaluated as PR (Figs.4 and 5). The patient underwent bilateral radical neck dissection and an almost total glossectomy reconstructed with a rectus abdominis myocutaneous flap. The histological effect was evaluated as II B (Fig.6).
Fig. 4. Magnetic resonance imaging (MRI) before chemotherapy of case 2. Arrow indicates left tongue cancer (T4N2cM0).

Fig. 5. This MRI reveals tumor regression of case 2 after chemotherapy (arrow). Clinical response is evaluated as PR.

Fig. 6. Histological findings of case 2 after chemotherapy. There is severe destruction of tumor structures with only a few viable tumor cells remaining that is assessed as grade II B.

Case 3
Case 3 was a 60-year-old male with right tongue cancer (T4N2bM0). After one cycle of the induction chemotherapy, marked response was observed but since the tumor was not palpable because the primary site was located at the back side of the dorsal tongue, the effect was evaluated as NC by means of MRI and CT (Figs. 7 and 8). The patient underwent bilateral radical neck dissection as well as hemiglossectomy and hemimandibulectomy reconstructed with a pectoralis major myocutaneous flap, but he died after 6 months. The histological effect was evaluated as II A (Fig. 9).
DISCUSSION

One of the outstanding characteristics of docetaxel is expression of cytotoxicity for cisplatin-resistant cancers [10]. Therefore, combination chemotherapy comprising docetaxel and cisplatin has recently been tested. For locally advanced cancers of the head and neck, the combination chemotherapy of docetaxel and cisplatin resulted in a response rate of 53% [11]. This is inferior to the rates achieved with the standard induction regimen of cisplatin and 5-FU [1,3,4]. On the contrary, docetaxel, cisplatin and 5-FU in all combinations have produced response rates of 90-93% [12,13,14]. In those previous studies, the number of administered cycles of chemotherapy was more than three, and the target diseases were head
and neck cancers. On the other hand, in this study the number of administered cycles was
decided as only one in order to decrease the total toxicity and reduce the period until radical
surgery. Moreover, we restricted the target disease to tongue carcinoma, because the
biological properties of head and neck cancers are not uniform due to regional peculiarities.
In order to further reduce the toxicity, the administration of cisplatin in this study was done
over a period of 5 days, with docetaxel preceding cisplatin [15,16].

Despite only one cycle of therapy, the overall response rate in this study was 83.3%. The
tumors were able to be excised more safely, and functional oral organs were occasionally
able to be preserved because of the tumor size reduction. Kirita et al. reported that residual
tumor cells after preoperative therapy were found by microscopy in the deep tissue where
there had been no clinical preoperative evidence of tumor invasion [17,18]. Their finding
warns us to excise more carefully at the deep margins of tumors. With regard to the time
interval between chemotherapy and surgery, the operation should not be delayed more than 5
weeks after the start of chemotherapy, since in this study the tumor size decreased greatly
during the first 3 weeks but tended to increase thereafter. Although the one patient with NC
had a poor outcome, there had been no apparent differences between the NC case and PR
cases except for the primary location on the tongue, indicating that it is difficult to estimate
the response before chemotherapy.

As for toxicity, side effects of more than grade III, consisted of leukopenia, neutropenia,
thrombocytopenia, alopecia and diarrhea, but all were able to be cured. Alopecia and
leukopenia or neutropenia were the most frequent, occurring in five patients (83.3%). Janinis
et al. and Posner et al. also reported severe neutropenia following the same regimen, but also
without any treatment-related deaths [12,13]. There were no instances of nausea, vomiting or
renal failure of more than grade III in this study.

In conclusion, one-cycle induction chemotherapy with docetaxel, cisplatin and 5-FU for
tongue cancer was tolerated well and yielded an excellent response rate. Since the survival
rate could not be determined because the follow-up was less than 24 months, further
long-term observations are required for a full assessment of the benefits and possible
drawbacks of this regimen.

REFERENCES
1. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC,
stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della
locoregional treatment for head and neck squamous-cell carcinoma: three
meta-analyses of updated individual data. MACH-NC Collaborative Group.
1996. Larynx preservation in pyriform sinus cancer: preliminary results of a European
88:890-8.
plus radiation compared with surgery plus radiation in patients with advanced laryngeal